Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Here are three no-brainer stocks to buy before the end of 2024 ... than Vertex's blockbuster drug Trikafta. It's also more powerful than Trikafta, and has a significantly lower royalty burden.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain Rating Scale after 12 weeks of treatment. Suzetrigine led to a ...

Detailed price information for Exxon Mobil Corp (XOM-N) from The Globe and Mail including charting and trades.

The data showed that after five years of treatment ... However, the company developed its competitive edge with the Trikafta treatment getting approved in 2019. Trikafta can treat approximately ...